# OnCo record b-cachexia-supportive (bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/bottlenecks/b-cachexia-supportive/>
  a schema:Thing ;
  onco:kind "bottleneck" ;
  schema:identifier "b-cachexia-supportive" ;
  schema:name "Cachexia, toxicity and the limits of the patient"@en ;
  schema:description "Cancer cachexia, the muscle and fat wasting driven by tumour and host inflammatory signals, affects most patients with advanced pancreatic, gastric and lung cancer, and treatment-limiting toxicities decide what dose a patient can receive. Only Japan has an approved cachexia drug, and supportive care research gets a small share of funding relative to its effect."@en ;
  schema:url <https://onco.cc/bottlenecks/b-cachexia-supportive/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(10)70218-7>, <https://doi.org/10.1056/NEJMoa2409515>, <https://doi.org/10.1200/JCO.20.00611> ;
  onco:related <https://onco.cc/ideas/idea-exercise-as-adjuvant/>, <https://onco.cc/ideas/idea-bio2-protein-plus-training-during-io/>, <https://onco.cc/ideas/idea-bio2-remote-weight-step-monitoring/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/exercise-oncology/>, <https://onco.cc/technologies/scalp-cooling/>, <https://onco.cc/technologies/geriatric-assessment/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:institutions <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/cruk/> ;
  onco:terms <https://onco.cc/terms/trastuzumab-cardiotoxicity/>, <https://onco.cc/terms/ild/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/irae/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-fearon-lancet-oncol/>, <https://onco.cc/key-papers/paper-roeland-j-clin-oncol/> .